about
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-UpEfficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, raImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrVirological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Genotypic resistance profiles of HIV-2-treated patients in West Africa.Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patientsBenefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trialPharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France.On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapyTransmitted drug resistance in French HIV-2-infected patients.Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAssociation of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys.Lopinavir/ritonavir population pharmacokinetics in neonates and infants.Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model.Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.The hairy-print for levamisole-induced vasculitis.Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.Predictors of virologic response to ritonavir-boosted protease inhibitors.Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirMutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancyPrediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsMitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments.Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal.Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient.Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
P50
Q28546894-D6AC1D20-79F5-45E3-B14C-61A55E960783Q31074302-B09DE13C-B2B8-4528-BD9F-BA05E06CE36FQ33267065-519CD8F4-F699-4A0D-88A9-81F6E554F549Q33769950-CC11D4C9-31A9-483D-8F4B-D0C53A94F07DQ33850152-E437F412-8D39-4863-A5A3-213074640DCDQ33954546-5EACCFE9-6049-4574-BBF2-0B4079AEDF0FQ34057304-75DCEC87-F680-4E73-8B94-A8401C5CCE62Q34057340-D0570DCA-1308-4310-8F12-84651BD5D0D6Q34103495-C68CCEC4-1C7D-47D8-BDA2-E368971B0DCAQ34158513-96BC394B-4BBC-436E-9BFD-71AA72FF96D3Q34328348-0F7CAF6F-B2FB-427D-85D2-CD771C5416AAQ34503668-19ECCC7C-E700-4FAE-B278-9D6A7E43F653Q34522575-698A4ADD-DBA4-4722-ADA4-4CC3DDA4C507Q34675595-C6F22CDE-A9D7-4406-B12F-BB60D783EA46Q34821530-373AC41E-4B5C-4CB7-8A24-BEC477A762DEQ34982615-09C8FF22-FA0F-4E5C-BEAE-E43622F442AFQ34996974-DAE8D9BF-4732-4BA7-83AA-34BE5B188953Q35005146-A8E59C46-F499-4994-944D-3A44761D6047Q35385930-13FB389D-585A-460E-BBC3-71AAD4C742BBQ35560174-25A0DA64-88FA-46D0-9181-E2ED2DD18D55Q35579403-71200A7A-EA49-4A94-9909-8929CA4A0B79Q35589798-8B66B5DF-E2F5-4BD3-A887-FA7A57C36813Q35628276-93EA8587-90DC-4F92-876C-D4A983EB95CEQ35666480-515DA7E0-96D4-41E9-A551-A1FAC4D05FE3Q35738681-43742825-1E62-4090-939E-79B61D35F7F4Q35979472-08E7D442-5D74-4648-95C2-B2DACA77C0D5Q36140405-743C2CA6-412D-4047-B4D2-7C8139F33521Q36373453-22160583-318B-4B33-9589-EAC8387372B5Q36424925-12785933-D4D9-48F1-BEC4-3684316CCDBAQ36538644-3558138F-6D3D-4105-9F5F-83DE36BFC3A1Q36538702-5EDEE07A-5071-4DA9-A565-873F6F652D43Q36538758-7D90A891-8746-4B40-97D8-0EF5B80182B7Q36706781-45B4A20A-12E5-40A3-A5EC-092BA1D6E402Q36813326-24D73A5A-A11F-4028-A841-2B2362023483Q36870850-4C9C9B12-6C74-43FF-87E7-E7160B2E1814Q36880847-271F2860-8F73-4DD1-80AF-26A6BABB11AEQ36887876-0BEB9682-FBF4-4C74-AB96-BD6BCCE2D9FAQ37379962-2B4439DB-DEC1-49CB-9694-1A17549228E4Q37410496-C4A8ABDB-F3F6-4F1A-8FCA-FEA67F6A6B94Q38394484-EF3E0CC1-409C-40A9-93E1-06D0C33A40CB
P50
name
Gilles Peytavin
@ast
Gilles Peytavin
@en
Gilles Peytavin
@es
Gilles Peytavin
@nl
type
label
Gilles Peytavin
@ast
Gilles Peytavin
@en
Gilles Peytavin
@es
Gilles Peytavin
@nl
prefLabel
Gilles Peytavin
@ast
Gilles Peytavin
@en
Gilles Peytavin
@es
Gilles Peytavin
@nl
P214
P214
P31
P735
P7859
viaf-54435166